Chronic verapamil therapy in pediatrie and young adult patients with hypertrophic cardiomyopathy

Robert L. Spicer, Albert P. Rocchini, Dennis C. Crowley, Amnon Rosenthal

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Oral verapamil, 5.2 ± 1.1 mg/kg/day (range 2.8 to 7), was administered to 13 pediatric patients with hypertrophic Cardiomyopathy for 13 ± 6 months (range 2 to 20). The patients had significant symptomatic improvement on verapamil therapy. Murmur intensity diminished in 6 patients during therapy and left ventricular (LV) electromotive forces on the electrocardiogram diminished in 4, increased in 5 and did not change in 4. Exercise endurance increased from 8.4 ± 3.9 to 10.9 ± 2.8 minutes (p < 0.01). Seven patients had ST-segment depression (0.38 ± 0.28 mV) before verapamil therapy, which improved after verapamil therapy in 5 (0.24 ± 0.17 mV, p < 0.02). Of 4 patients with exercise-induced ventricular ectopic activity, 3 had diminution or abolishment of ectopy following verapamil. By echocardiography, the patients had an increase in LV end-diastolic dimension from 3.4 ± 0.7 to 3.9 ± 0.8 cm (p < 0.01), with no significant change in shortening fraction (46.1 ± 8.0% vs 44.6 ± 8.0%). When adjusted for body size and age there was a significant decrease in LV septal thickness (from 106 ± 70 to 45 ± 52% of predicted normal values, p < 0.05) and LV posterior wall thickness (from 40 ± 45 to 5 ± 26% of predicted normal values p = 0.05) after verapamil. Isovolumic relaxation time decreased from 69 ± 26 to 42 ± 19 ms after verapamil (p < 0.01). Systolic anterior motion of the anterior mitral leaflet disappeared in 5 of 8 patients and midsystolic closure of the aortic valve was no longer present in 4 of 8. Chronic oral verapamil appears to be an effective form of therapy for pediatric patients with hypertrophic Cardiomyopathy.

Original languageEnglish (US)
Pages (from-to)1614-1619
Number of pages6
JournalThe American Journal of Cardiology
Volume53
Issue number11
DOIs
StatePublished - Jun 1 1984

Fingerprint

Hypertrophic Cardiomyopathy
Verapamil
Young Adult
Therapeutics
Reference Values
Exercise
Pediatrics
Body Size
Aortic Valve
Echocardiography
Electrocardiography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Chronic verapamil therapy in pediatrie and young adult patients with hypertrophic cardiomyopathy. / Spicer, Robert L.; Rocchini, Albert P.; Crowley, Dennis C.; Rosenthal, Amnon.

In: The American Journal of Cardiology, Vol. 53, No. 11, 01.06.1984, p. 1614-1619.

Research output: Contribution to journalArticle

Spicer, Robert L. ; Rocchini, Albert P. ; Crowley, Dennis C. ; Rosenthal, Amnon. / Chronic verapamil therapy in pediatrie and young adult patients with hypertrophic cardiomyopathy. In: The American Journal of Cardiology. 1984 ; Vol. 53, No. 11. pp. 1614-1619.
@article{bfb806e21fc042b4b444d925437fcf1a,
title = "Chronic verapamil therapy in pediatrie and young adult patients with hypertrophic cardiomyopathy",
abstract = "Oral verapamil, 5.2 ± 1.1 mg/kg/day (range 2.8 to 7), was administered to 13 pediatric patients with hypertrophic Cardiomyopathy for 13 ± 6 months (range 2 to 20). The patients had significant symptomatic improvement on verapamil therapy. Murmur intensity diminished in 6 patients during therapy and left ventricular (LV) electromotive forces on the electrocardiogram diminished in 4, increased in 5 and did not change in 4. Exercise endurance increased from 8.4 ± 3.9 to 10.9 ± 2.8 minutes (p < 0.01). Seven patients had ST-segment depression (0.38 ± 0.28 mV) before verapamil therapy, which improved after verapamil therapy in 5 (0.24 ± 0.17 mV, p < 0.02). Of 4 patients with exercise-induced ventricular ectopic activity, 3 had diminution or abolishment of ectopy following verapamil. By echocardiography, the patients had an increase in LV end-diastolic dimension from 3.4 ± 0.7 to 3.9 ± 0.8 cm (p < 0.01), with no significant change in shortening fraction (46.1 ± 8.0{\%} vs 44.6 ± 8.0{\%}). When adjusted for body size and age there was a significant decrease in LV septal thickness (from 106 ± 70 to 45 ± 52{\%} of predicted normal values, p < 0.05) and LV posterior wall thickness (from 40 ± 45 to 5 ± 26{\%} of predicted normal values p = 0.05) after verapamil. Isovolumic relaxation time decreased from 69 ± 26 to 42 ± 19 ms after verapamil (p < 0.01). Systolic anterior motion of the anterior mitral leaflet disappeared in 5 of 8 patients and midsystolic closure of the aortic valve was no longer present in 4 of 8. Chronic oral verapamil appears to be an effective form of therapy for pediatric patients with hypertrophic Cardiomyopathy.",
author = "Spicer, {Robert L.} and Rocchini, {Albert P.} and Crowley, {Dennis C.} and Amnon Rosenthal",
year = "1984",
month = "6",
day = "1",
doi = "10.1016/0002-9149(84)90589-7",
language = "English (US)",
volume = "53",
pages = "1614--1619",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Chronic verapamil therapy in pediatrie and young adult patients with hypertrophic cardiomyopathy

AU - Spicer, Robert L.

AU - Rocchini, Albert P.

AU - Crowley, Dennis C.

AU - Rosenthal, Amnon

PY - 1984/6/1

Y1 - 1984/6/1

N2 - Oral verapamil, 5.2 ± 1.1 mg/kg/day (range 2.8 to 7), was administered to 13 pediatric patients with hypertrophic Cardiomyopathy for 13 ± 6 months (range 2 to 20). The patients had significant symptomatic improvement on verapamil therapy. Murmur intensity diminished in 6 patients during therapy and left ventricular (LV) electromotive forces on the electrocardiogram diminished in 4, increased in 5 and did not change in 4. Exercise endurance increased from 8.4 ± 3.9 to 10.9 ± 2.8 minutes (p < 0.01). Seven patients had ST-segment depression (0.38 ± 0.28 mV) before verapamil therapy, which improved after verapamil therapy in 5 (0.24 ± 0.17 mV, p < 0.02). Of 4 patients with exercise-induced ventricular ectopic activity, 3 had diminution or abolishment of ectopy following verapamil. By echocardiography, the patients had an increase in LV end-diastolic dimension from 3.4 ± 0.7 to 3.9 ± 0.8 cm (p < 0.01), with no significant change in shortening fraction (46.1 ± 8.0% vs 44.6 ± 8.0%). When adjusted for body size and age there was a significant decrease in LV septal thickness (from 106 ± 70 to 45 ± 52% of predicted normal values, p < 0.05) and LV posterior wall thickness (from 40 ± 45 to 5 ± 26% of predicted normal values p = 0.05) after verapamil. Isovolumic relaxation time decreased from 69 ± 26 to 42 ± 19 ms after verapamil (p < 0.01). Systolic anterior motion of the anterior mitral leaflet disappeared in 5 of 8 patients and midsystolic closure of the aortic valve was no longer present in 4 of 8. Chronic oral verapamil appears to be an effective form of therapy for pediatric patients with hypertrophic Cardiomyopathy.

AB - Oral verapamil, 5.2 ± 1.1 mg/kg/day (range 2.8 to 7), was administered to 13 pediatric patients with hypertrophic Cardiomyopathy for 13 ± 6 months (range 2 to 20). The patients had significant symptomatic improvement on verapamil therapy. Murmur intensity diminished in 6 patients during therapy and left ventricular (LV) electromotive forces on the electrocardiogram diminished in 4, increased in 5 and did not change in 4. Exercise endurance increased from 8.4 ± 3.9 to 10.9 ± 2.8 minutes (p < 0.01). Seven patients had ST-segment depression (0.38 ± 0.28 mV) before verapamil therapy, which improved after verapamil therapy in 5 (0.24 ± 0.17 mV, p < 0.02). Of 4 patients with exercise-induced ventricular ectopic activity, 3 had diminution or abolishment of ectopy following verapamil. By echocardiography, the patients had an increase in LV end-diastolic dimension from 3.4 ± 0.7 to 3.9 ± 0.8 cm (p < 0.01), with no significant change in shortening fraction (46.1 ± 8.0% vs 44.6 ± 8.0%). When adjusted for body size and age there was a significant decrease in LV septal thickness (from 106 ± 70 to 45 ± 52% of predicted normal values, p < 0.05) and LV posterior wall thickness (from 40 ± 45 to 5 ± 26% of predicted normal values p = 0.05) after verapamil. Isovolumic relaxation time decreased from 69 ± 26 to 42 ± 19 ms after verapamil (p < 0.01). Systolic anterior motion of the anterior mitral leaflet disappeared in 5 of 8 patients and midsystolic closure of the aortic valve was no longer present in 4 of 8. Chronic oral verapamil appears to be an effective form of therapy for pediatric patients with hypertrophic Cardiomyopathy.

UR - http://www.scopus.com/inward/record.url?scp=0021243937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021243937&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(84)90589-7

DO - 10.1016/0002-9149(84)90589-7

M3 - Article

C2 - 6539561

AN - SCOPUS:0021243937

VL - 53

SP - 1614

EP - 1619

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 11

ER -